We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+2.29%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.1B
AUM Growth
+$93.7M
Cap. Flow
+$96.1M
Cap. Flow %
8.76%
Top 10 Hldgs %
40.44%
Holding
102
New
24
Increased
37
Reduced
19
Closed
19

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$22.3M
2
ABT icon
Abbott
ABT
+$15.9M
3
NTRA icon
Natera
NTRA
+$12.9M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$12.8M
5
MMSI icon
Merit Medical Systems
MMSI
+$12.7M

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$23.2M
2
MDT icon
Medtronic
MDT
+$20.5M
3
MRK icon
Merck
MRK
+$19.8M
4
CNC icon
Centene
CNC
+$18.9M
5
UTHR icon
United Therapeutics
UTHR
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 85.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THC icon
1
Tenet Healthcare
THC
$16.7B
$75.2M 6.86%
398,567
+800
+0.2% +$169K
LLY icon
2
Eli Lilly
LLY
$1.05T
$60.5M 5.52%
65,762
-2,527
-4% -$2.56M
XBI icon
3
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$58.2M 5.3%
+455,300
New +$56.8M
PEN icon
4
Penumbra
PEN
$12.5B
$45.9M 4.19%
139,779
-5,392
-4% -$1.83M
AXSM icon
5
Axsome Therapeutics
AXSM
$11.4B
$44.7M 4.07%
264,304
+12,742
+5% +$2.2M
XLV icon
6
CALL
State Street Health Care Select Sector SPDR ETF
XLV
$41.5B
$35M 3.19%
+238,900
New +$36.9M
ASND icon
7
Ascendis Pharma A/S
ASND
$16.7B
$34.8M 3.17%
152,034
-25,651
-14% -$5.75M
JAZZ icon
8
Jazz Pharmaceuticals
JAZZ
$15.3B
$33.7M 3.07%
178,144
+127,633
+253% +$22.3M
NBIX icon
9
Neurocrine Biosciences
NBIX
$18B
$28.4M 2.59%
215,678
+52,481
+32% +$6.96M
UTHR icon
10
PUT
United Therapeutics
UTHR
$26.4B
$27.2M 2.48%
+45,900
New +$22.9M
UTHR icon
11
United Therapeutics
UTHR
$26.4B
$23.6M 2.15%
39,805
-27,938
-41% -$13.9M
GKOS icon
12
Glaukos
GKOS
$8.99B
$23.2M 2.12%
215,685
+14,009
+7% +$1.58M
CNTA
13
DELISTED
Centessa Pharmaceuticals
CNTA
$21M 1.91%
528,224
-63,377
-11% -$1.62M
INBX icon
14
Inhibrx
INBX
$1.23B
$20.5M 1.87%
305,431
+39,914
+15% +$2.96M
EW icon
15
Edwards Lifesciences
EW
$48.9B
$20.4M 1.86%
254,510
+7,675
+3% +$633K
BBIO icon
16
BridgeBio Pharma
BBIO
$15.8B
$19.1M 1.75%
257,747
-48,759
-16% -$3.53M
UTHR icon
17
CALL
United Therapeutics
UTHR
$26.4B
$18.8M 1.71%
+31,700
New +$15.8M
MDGL icon
18
Madrigal Pharmaceuticals
MDGL
$12.6B
$17.9M 1.63%
34,146
+26,888
+370% +$12.8M
INDV icon
19
Indivior Pharmaceuticals
INDV
$4.62B
$17.5M 1.6%
574,666
+213,971
+59% +$7.07M
UNH icon
20
UnitedHealth
UNH
$396B
$15.7M 1.43%
58,038
+7,499
+15% +$2.23M
DNTH icon
21
Dianthus Therapeutics
DNTH
$5.78B
$14.4M 1.32%
172,137
+72,561
+73% +$4.2M
ABT icon
22
Abbott
ABT
$174B
$14.4M 1.31%
+140,432
New +$15.9M
RVMD icon
23
Revolution Medicines
RVMD
$38.4B
$13.7M 1.25%
140,770
-10,683
-7% -$1.08M
ACHC icon
24
Acadia Healthcare
ACHC
$3.27B
$13.6M 1.24%
+582,745
New +$10.5M
NEO icon
25
NeoGenomics
NEO
$1.85B
$13.2M 1.21%
1,784,552
+90,501
+5% +$952K
1
2 3 4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
CPRC
Consolidated Portfolio Review Corp Woodbury, New York $1.1B AUM 8.96% 1-Year Est. Return
AWP
Abacus Wealth Partners Santa Monica, California $1.1B AUM 14.74% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

PFM Health Sciences's Q1 2026 Portfolio in Review

As of Q1 2026, PFM Health Sciences held 102 positions worth $1.1B, up 9.3% from $1B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

PFM Health Sciences deployed $96.1M of net new capital in Q1 2026, opening 24 new positions and adding to 37 existing holdings. Its largest new stake was Abbott: 140,432 shares worth $14.4M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Centene, an estimated $18.9M trimmed.

  • PFM Health Sciences's largest Q1 2026 buy was Abbott: 140,432 shares worth $14.4M.
  • PFM Health Sciences added most to Jazz Pharmaceuticals in Q1 2026, an estimated $22.3M increase.
  • PFM Health Sciences's biggest Q1 2026 reduction was Centene, cutting an estimated $18.9M.
  • PFM Health Sciences fully exited ADMA Biologics in Q1 2026, selling an estimated $23.2M.
  • PFM Health Sciences's ten largest holdings make up 40% of its $1.1B portfolio in Q1 2026.
  • PFM Health Sciences opened 24 new positions and closed 19 in Q1 2026.
  • PFM Health Sciences's portfolio value rose 9.3% quarter-over-quarter to $1.1B.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.